- Home
- PLMR vs TARS Comparison
PLMR vs TARS Comparison
Compare PLMR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | TARS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLMR | TARS |
|---|---|---|
| Price | $137.56 | $58.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $153.60 | $89.00 |
| AVG Volume (30 Days) | 328.9K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | 48.21 |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $875,967,000.00 | $451,360,000.00 |
| Revenue This Year | $192.25 | $56.43 |
| Revenue Next Year | $19.34 | $30.19 |
| P/E Ratio | $82.28 | ★ N/A |
| Revenue Growth | 58.16 | ★ 146.71 |
| 52 Week Low | $100.81 | $38.51 |
| 52 Week High | $147.62 | $85.25 |
Technical Indicators
Market Signals| Indicator | PLMR | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 45.13 |
| Support Level | $112.49 | $56.05 |
| Resistance Level | $136.20 | $67.14 |
| Average True Range (ATR) | 5.46 | 3.54 |
| MACD | -1.28 | -0.35 |
| Stochastic Oscillator | 42.04 | 23.72 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.